WeedMD Inc (TSXV: WMD) announced this morning that it had secured from Health Canada an amendment to its existing cultivation license at its Strathroy, Ontario site. The amendment allows for cultivation and processing in twenty additional rooms, bringing the grand total to twenty cultivation rooms for the facility.
Sitting at 10,000 square feet in size each, there are now a total of eighteen licensed cultivation rooms at the site, plus two 5,000 square foot nurseries, bringing total indoor production to over 20,000 KG per annum. Meanwhile, the additional processing rooms will be utilizing for trimming, drying, and processing the cannabis grown in the recently licensed space.
This capacity is in addition to the 27 acres of outdoor cannabis that is currently in production on site as well. Officially, WeedMD states that it is expecting approximately 25,000 KG of biomass from its outdoor grow, however a recent report by Haywood Securities nearly doubled that estimate, stating it expects 45,000 KG of cannabis based on current site conditions.
“In the past year we have successfully expanded our production capacity more than 20-fold, and brought online an efficient quality-driven production platform that is recognized across Canada as a trusted source of medical-grade cannabis. The scalability of our production, together with our extraction capabilities at CX Industries, gives us the platform to continue delivering the results that our stakeholders expect.”Keith Merker, CEO of WeedMD
With the latest amendment, WeedMD now has over 215,000 square feet of licensed indoor production space. This is expected to increase to approximately 523,000 square feet upon the licensing of the final phase of the Strathroy facility, which consists of over 308,000 square feet of greenhouse space. This final phase is expected to come online early in 2020 upon licensing from Health Canada.
Lastly, the Strathroy, Ontario facility has an additional 73 acres of outdoor production expected to come online next year.
FULL DISCLOSURE: WeedMD is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover WeedMD on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.